Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CSGALNACT1 | Q8TDX6 | 8/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.43 |
| ▸ | EIF2S1 | P05198 | 1/20 | 0.42 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180372 | 1.00 | MEN1 (0.46) | MEN1KMT2AKDM4EALDH1A1CSGALNACT1 | |
| SCHEMBL12872658 | 0.94 | KMT2A (0.46) | MEN1KMT2AKDM4EALDH1A1EIF2S1 | |
| SCHEMBL1180113 | 0.90 | MAPT (0.48) | ALDH1A1CSGALNACT1DGAT1NPC1RAB9A | |
| SCHEMBL1180109 | 0.90 | MAPT (0.48) | ALDH1A1CSGALNACT1DGAT1NPC1RAB9A | |
| SCHEMBL12872641 | 0.87 | MEN1 (0.48) | MEN1KMT2AKDM4EALDH1A1EIF2S1 | |
| SCHEMBL1180677 | 0.85 | MEN1 (0.46) | MEN1KMT2AKDM4EALDH1A1EIF2S1 | |
| SCHEMBL12872713 | 0.84 | CSGALNACT1 (0.60) | CSGALNACT1DGAT1 | |
| SCHEMBL1179590 | 0.84 | ALDH1A1 (0.55) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL12872602 | 0.83 | MAPT (0.48) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL1180234 | 0.82 | ADAMTS4 (0.41) | CSGALNACT1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| WO-2009126624-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | MEN1 4094/4885KMT2A 1596/4885KDM4E 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.